Denosumab, the humanized monoclonal antibody against RANKL, is the first biological therapy for osteoporosis by inhibiting the osteoprotegerin (OPG)/RANKL/RANK pathway, which plays a pivotal role in bone metabolism via stimulating osteoclastogenesis and thereby promoting bone resorption [22,23]. This evidence concerns the gene TNFSF11 and osteoporosis.